COVID-19 Infection in Multiple Sclerosis Patients Treated with Rituximab Compared to Natalizumab and Healthy Controls: A Real-World Multicenter Study Tekijä Thomas Mathew, Surabhi Garg, Saji K. John, Mal S. Kimi, Naom Z. Chhakchhuak, Sherina Koshy, Tenzin Yangdonq, Molly George, Shagun Bhardwaj, Yerasu M. Reddy, Uday Murgod, Vikram Kamath, Sonia Shivde, Sagar Badachi, Akshata Huddar, Gosala R. K. Sarma, Raghunandan Nadig

Hae kokoteksti